

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Please cancel claims 2, 3, 6, 8, 15, 17-19, and 22-29 without prejudice.

Please amend claims 1, 7, and 21 as follows:

1. A method of stimulating an immune response against a tumor antigen in a mammal, the method comprising administering to said mammal said tumor antigen and a lactadherin or a [fragment thereof] polypeptide comprising a lactadherin amino acid sequence, said [fragment] polypeptide comprising a functional integrin binding site of lactadherin represented by the RGD motif.
7. The method of any one of claims 1-5, wherein said polypeptide is human lactadherin or [fragment thereof is human lactadherin or] a polypeptide comprising a functional integrin binding site of human lactadherin [fragment thereof].
21. The method of claim [19] 1, wherein said lactadherin has the amino acid sequence of SEQ ID NO: 2 or 4 or a [fragment] part thereof comprising of a functional integrin binding site, said part comprising amino acid residues Arg Gly Asp at position 46-48 of SEQ ID NO: 2 or amino acid residues 87-89 or SEQ ID NO: 4.